PRIMARY OBJECTIVES:
I. Assess feasibility and toxicity of single-fraction stereotactic body radiation therapy (SBRT) in the post-operative setting.
SECONDARY OBJECTIVES:
I. Assess quality of life following post-operative single-fraction SBRT. II. Assess rate of in-field failures.
TERTIARY OBJECTIVES:
I. Assess progression free survival and overall survival following post-operative SBRT for stage III/IV non-small cell lung cancer (NSCLC).
EXPLORATORY OBJECTIVES:
I. Changes in the inflammatory markers.
OUTLINE:
Beginning at least 2 weeks after surgical resection, patients undergo 1 fraction (or 5 fractions every other day if R2 resection of central tumor) of SBRT.
After completion of study treatment, patients are followed up at 5 and 12 weeks and then periodically for up to 5 years.